CA2446916A1 - Delivery of opioids through an inhalation route - Google Patents

Delivery of opioids through an inhalation route Download PDF

Info

Publication number
CA2446916A1
CA2446916A1 CA002446916A CA2446916A CA2446916A1 CA 2446916 A1 CA2446916 A1 CA 2446916A1 CA 002446916 A CA002446916 A CA 002446916A CA 2446916 A CA2446916 A CA 2446916A CA 2446916 A1 CA2446916 A1 CA 2446916A1
Authority
CA
Canada
Prior art keywords
aerosol
morphine
remifentanil
nalbuphine
meperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002446916A
Other languages
French (fr)
Other versions
CA2446916C (en
Inventor
Joshua D. Rabinowitz
Alejandro C. Zaffaroni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexza Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2002/016099 external-priority patent/WO2002094234A1/en
Publication of CA2446916A1 publication Critical patent/CA2446916A1/en
Application granted granted Critical
Publication of CA2446916C publication Critical patent/CA2446916C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F24—HEATING; RANGES; VENTILATING
    • F24V—COLLECTION, PRODUCTION OR USE OF HEAT NOT OTHERWISE PROVIDED FOR
    • F24V30/00—Apparatus or devices using heat produced by exothermal chemical reactions other than combustion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
    • A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/82—Internal energy supply devices
    • A61M2205/8206—Internal energy supply devices battery-operated

Abstract

The present invention relates to the delivery of opioids through an inhalation route. Specifically, it relates to aerosols containing opioids that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an opioid. In a method aspect of the present invention, an opioid is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an opioid, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an opioid through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an opioid; and, b) a device that forms an opioid aerosol from the composition, for inhalation by the mammal.

Claims (15)

1. An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of an opioid, and wherein the opioid is not morphine or heroin.
2. An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
3. The aerosol according to Claim 2, wherein the aerosol particles have a mass median aerodynamic diameter of less than 3 microns.
4. The aerosol according to Claim 2, wherein the particles comprise less than
5 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butoxphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil degradation products.

5. The aerosol according to Claim 2, wherein the aerosol comprises particles comprising at least 90 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
6. The aerosol according to Claim 5, wherein the aerosol particles have a mass median aerodynamic diameter less than 2 microns.
7. The aerosol according to Claim 6, wherein the aerosol comprises particles comprising at least 95 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
8. A method of delivering morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil to a mammal through an inhalation route, wherein the route comprises:
a) heating a composition, wherein the composition comprises at least 5 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.
9. The method according to Claim 8, wherein the particles comprise at least 10 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
10. The method according to Claim 8, wherein the aerosol particles have a mass median aerodynamic diameter of less than 3 microns.
11. The method according to Claim 8, wherein the particles comprise less than percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil degradation products.
12. The method according to Claim 10, wherein the aerosol comprises particles comprising at least 90 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
13. The method according to Claim 12, wherein the aerosol particles have a mass median aerodynamic diameter less than 2 microns.
14. The method according to Claim 13, wherein the aerosol comprises particles comprising at least 95 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
15. A kit for delivering morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil through an inhalation route to a mammal, wherein the kit comprises:
a) a composition comprising at least 5 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil; and, b) a device that forms a morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil aerosol from the composition, for inhalation by the mammal and wherein the device comprises:
a) an element for heating the morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil composition to form a vapor;
b) an element allowing the vapor to cool to form an aerosol; and, c) an element permitting the mammal to inhale the aerosol.
CA002446916A 2001-05-24 2002-05-21 Delivery of opioids through an inhalation route Expired - Fee Related CA2446916C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29420301P 2001-05-24 2001-05-24
US60/294,203 2001-05-24
US31747901P 2001-09-05 2001-09-05
US60/317,479 2001-09-05
PCT/US2002/016099 WO2002094234A1 (en) 2001-05-24 2002-05-21 Delivery of opioids through an inhalation route

Publications (2)

Publication Number Publication Date
CA2446916A1 true CA2446916A1 (en) 2002-11-28
CA2446916C CA2446916C (en) 2009-12-22

Family

ID=30772632

Family Applications (7)

Application Number Title Priority Date Filing Date
CA002446904A Abandoned CA2446904A1 (en) 2001-05-24 2002-05-13 Delivery of drug esters through an inhalation route
CA002446990A Expired - Fee Related CA2446990C (en) 2001-05-24 2002-05-17 Delivery of sedative-hypnotics through an inhalation route
CA002446917A Expired - Lifetime CA2446917C (en) 2001-05-24 2002-05-20 Delivery of antipsychotics through an inhalation route
CA002447521A Expired - Fee Related CA2447521C (en) 2001-05-24 2002-05-21 Delivery of antihistamines through an inhalation route
CA002446916A Expired - Fee Related CA2446916C (en) 2001-05-24 2002-05-21 Delivery of opioids through an inhalation route
CA002447166A Expired - Fee Related CA2447166C (en) 2001-05-24 2002-05-22 Delivery of erectile dysfunction drugs through an inhalation route
CA2447099A Expired - Fee Related CA2447099C (en) 2001-05-24 2002-05-23 Delivery of compounds for the treatment of migraine through an inhalation route

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CA002446904A Abandoned CA2446904A1 (en) 2001-05-24 2002-05-13 Delivery of drug esters through an inhalation route
CA002446990A Expired - Fee Related CA2446990C (en) 2001-05-24 2002-05-17 Delivery of sedative-hypnotics through an inhalation route
CA002446917A Expired - Lifetime CA2446917C (en) 2001-05-24 2002-05-20 Delivery of antipsychotics through an inhalation route
CA002447521A Expired - Fee Related CA2447521C (en) 2001-05-24 2002-05-21 Delivery of antihistamines through an inhalation route

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA002447166A Expired - Fee Related CA2447166C (en) 2001-05-24 2002-05-22 Delivery of erectile dysfunction drugs through an inhalation route
CA2447099A Expired - Fee Related CA2447099C (en) 2001-05-24 2002-05-23 Delivery of compounds for the treatment of migraine through an inhalation route

Country Status (16)

Country Link
US (75) US6737042B2 (en)
EP (14) EP1392262A1 (en)
JP (7) JP2005503425A (en)
AT (11) ATE462420T1 (en)
AU (3) AU2002314784A1 (en)
BE (1) BE2013C054I2 (en)
CA (7) CA2446904A1 (en)
DE (4) DE60235851D1 (en)
DK (1) DK1389098T3 (en)
ES (5) ES2312571T3 (en)
FR (1) FR13C0051I1 (en)
MX (2) MXPA03010703A (en)
NZ (6) NZ529422A (en)
PL (3) PL363996A1 (en)
PT (2) PT1389098E (en)
WO (1) WO2002094236A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082369A1 (en) * 2003-02-28 2005-09-09 Delex Therapeutics Inc. Opioid delivery system
JP2006519185A (en) * 2003-02-28 2006-08-24 デレックス・セラピューティクス・インコーポレイテッド Opioid delivery system
US7648982B2 (en) 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US7648981B2 (en) 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system

Families Citing this family (367)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
DE60030870T2 (en) * 1999-07-12 2007-05-10 Capnia Inc., Los Gatos ARRANGEMENT FOR THE TREATMENT OF HEADACHE, RHINITIS AND OTHER SUFFERING
US6959708B1 (en) * 1999-11-08 2005-11-01 Capnia, Incorporated Method for co-application of gases and drugs to potentiate their action in relieving headaches, angina and other ailments
US20060172017A1 (en) 1999-11-08 2006-08-03 Capnia, Incorporated Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
US20070039615A1 (en) * 1999-11-08 2007-02-22 Capnia, Incorporated Methods and apparatus for treating rhinitis
US6888106B2 (en) * 2000-04-07 2005-05-03 Ibiden Co., Ltd. Ceramic heater
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
WO2002009669A2 (en) * 2000-08-01 2002-02-07 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution and particles made thereby
US20020169507A1 (en) 2000-12-14 2002-11-14 David Malone Interbody spine fusion cage
SE0101204D0 (en) * 2001-04-04 2001-04-04 Siemens Elema Ab Heating device for respiratory gas
US7458374B2 (en) * 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
JP2005503425A (en) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション Delivery of drug ester by the prescribed inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
JP4357842B2 (en) * 2001-05-24 2009-11-04 アレックザ ファーマシューティカルズ， インコーポレイテッド Delivery of alprazolam, estazolam, midazolam or triazolam by a prescribed inhalation route
US7766013B2 (en) * 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US6759029B2 (en) 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
WO2003057188A1 (en) * 2001-11-21 2003-07-17 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
EP1455875A2 (en) * 2001-11-21 2004-09-15 Alexza Molecular Delivery Corporation Open-celled substrates for drug delivery
US7523065B2 (en) * 2001-12-12 2009-04-21 Asset Trust, Inc. Risk transfer supply chain system
GB2384184B (en) * 2002-01-10 2005-01-12 Aea Technology Plc Cannabis aerosol
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
EP1503744A1 (en) * 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US20060193788A1 (en) * 2002-11-26 2006-08-31 Hale Ron L Acute treatment of headache with phenothiazine antipsychotics
BR0311693A (en) * 2002-06-10 2005-03-22 Wyeth Corp O-desmethyl-venlafaxine salt
DE10234165B4 (en) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale A method of filling a trench formed in a substrate with an insulating material
US20040076671A1 (en) * 2002-10-21 2004-04-22 Aletha Tippett Methods and compositions for topical wound treatment
US7644715B2 (en) * 2002-10-31 2010-01-12 Cooltouch, Incorporated Restless leg syndrome treatment
JP2006514633A (en) * 2002-11-26 2006-05-11 アレックザ ファーマシューティカルズ， インコーポレイテッド Treatment of headache with antipsychotics delivered by inhalation
CA2507159A1 (en) * 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
EP1596824A4 (en) * 2003-02-04 2011-11-23 Chrysalis Tech Inc Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
CA2522231A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
JP4601619B2 (en) 2003-05-21 2010-12-22 アレックザ ファーマシューティカルズ， インコーポレイテッド Built-in heating unit and medicine supply unit using the same
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
CN2718561Y (en) * 2003-07-11 2005-08-17 艾康生物技术(杭州)有限公司 Protective cover for withdrawing sample label
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
JP4869927B2 (en) * 2003-08-04 2012-02-08 アレックザ ファーマシューティカルズ， インコーポレイテッド Substrates and preparation methods and uses for drug delivery devices
US20050037506A1 (en) * 2003-08-04 2005-02-17 Alexza Molecular Delivery Corporation Methods of determining film thicknesses for an aerosol delivery article
AU2004272077A1 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
AU2004271779A1 (en) * 2003-09-15 2005-03-24 Vectura Limited Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
CN1305266C (en) * 2003-12-19 2007-03-14 深圳国人通信有限公司 Radio local area network cut-in point device based on embedded system
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US20050256553A1 (en) * 2004-02-09 2005-11-17 John Strisower Method and apparatus for the treatment of respiratory and other infections using ultraviolet germicidal irradiation
US20070280159A1 (en) * 2004-03-04 2007-12-06 Utstarcom Telecom Co., Ltd Load-Sharing Method And System In A Wireless Base Station
US7422224B2 (en) * 2004-04-13 2008-09-09 Kimir Seatpost Adjustable bicycle seat post assembly
US7402777B2 (en) 2004-05-20 2008-07-22 Alexza Pharmaceuticals, Inc. Stable initiator compositions and igniters
US7540286B2 (en) * 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20100006092A1 (en) * 2004-08-12 2010-01-14 Alexza Pharmaceuticals, Inc. Aerosol Drug Delivery Device Incorporating Percussively Activated Heat Packages
US20060039869A1 (en) * 2004-08-17 2006-02-23 Daniel Wermeling Intranasal delivery of antipsychotic drugs
US20060120962A1 (en) * 2004-10-12 2006-06-08 Rabinowitz Joshua D Cardiac safe, rapid medication delivery
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
JP5355893B2 (en) * 2004-12-16 2013-11-27 シプラ・リミテッド Method for producing pantoprazole sodium
US20060130829A1 (en) * 2004-12-20 2006-06-22 Sexton Douglas A Inhalation device
US7827983B2 (en) * 2004-12-20 2010-11-09 Hewlett-Packard Development Company, L.P. Method for making a pharmaceutically active ingredient abuse-prevention device
WO2006117700A2 (en) * 2005-04-21 2006-11-09 Medichem, S.A. Process for preparing quetiapine and quetiapine fumarate
US20090117660A1 (en) * 2005-04-30 2009-05-07 Oakville Hong Kong Co., Limited Devices and methods for sample collection and analysis
US8062901B2 (en) * 2005-04-30 2011-11-22 Alere Switzerland Gmbh Devices and methods for sample collection and analysis
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
WO2007016361A2 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
CA2622200A1 (en) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
US20070092401A1 (en) * 2005-10-26 2007-04-26 Feier Liao Devices and methods for sample collection and analysis
EP1957862B1 (en) * 2005-12-01 2017-01-04 Vapore, LLC Apparatus and method for the generation of pressurized vapor from a liquid
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8252329B2 (en) * 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
WO2007083073A1 (en) 2006-01-19 2007-07-26 Optinose As Nasal administration
US20070183351A1 (en) * 2006-02-03 2007-08-09 Motorola, Inc. Method and apparatus for providing service in a multi-ran communication network
WO2007123945A2 (en) * 2006-04-21 2007-11-01 Aradigm Corporation Mechanical single dose intrapulmonary drug delivery devices
US7909033B2 (en) 2006-05-03 2011-03-22 Comedica Incorporated Breathing treatment apparatus
US8536445B2 (en) * 2006-06-02 2013-09-17 Emcore Solar Power, Inc. Inverted metamorphic multijunction solar cells
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
US8051854B2 (en) * 2006-09-15 2011-11-08 Comedica Incorporated Continuous high-frequency oscillation breathing treatment apparatus
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
GB0620661D0 (en) * 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
US20080102097A1 (en) * 2006-10-31 2008-05-01 Zanella John M Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent
US8279765B2 (en) * 2006-11-13 2012-10-02 Motorola Solutions, Inc. Method and apparatus for interworking in an inter-technology network
US20080154374A1 (en) * 2006-12-20 2008-06-26 Robert David Labrom Joint implant and a surgical method associated therewith
WO2008080170A1 (en) * 2006-12-22 2008-07-03 Alexza Pharmaceuticals, Inc. Mixed drug aerosol compositiions
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
HUE026884T2 (en) 2007-02-11 2016-08-29 Map Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
ES2594867T3 (en) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US8759383B2 (en) 2007-03-16 2014-06-24 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
WO2008116165A2 (en) * 2007-03-21 2008-09-25 Next Safety, Inc. Methods and systems of delivering medication via inhalation
US20080261926A1 (en) * 2007-04-02 2008-10-23 Liu Julie F Pharmaceutical Calcimimetics
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
EP2134323A4 (en) * 2007-04-06 2012-03-07 Rhode Island Education Lowering of proteins associated with alzheimer's disease by interrupting gene transcription with a small molecule
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
JP2010524972A (en) * 2007-04-19 2010-07-22 コンサート ファーマシューティカルズ インコーポレイテッド Deuterated morpholinyl compounds
WO2008133949A1 (en) 2007-04-25 2008-11-06 Concert Pharmaceuticals, Inc. Analogues of cilostazol
DK3825306T3 (en) 2007-05-01 2023-09-11 Sun Pharmaceutical Ind Inc MORPHINE COMPOUNDS
US7608737B2 (en) 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
EP4183787A1 (en) 2007-05-01 2023-05-24 Concert Pharmaceuticals Inc. Morphinan compounds
MX2009011958A (en) * 2007-05-01 2010-06-30 Concert Pharmaceuticals Inc Morphinan compounds.
WO2008141021A1 (en) * 2007-05-08 2008-11-20 Concert Pharmaceuticals, Inc. Deuterated derivatives of tetrahydrotriazolopyrazine compounds and their use as dpp-iv inhibitors
US9050434B2 (en) * 2007-05-18 2015-06-09 Comedica Incorporated Lung therapy device
RU2448958C2 (en) 2007-06-12 2012-04-27 Консерт Фармасьютикалз, Инк. Azapeptide derivatives
WO2009009531A2 (en) * 2007-07-09 2009-01-15 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives for the treatment of hiv infections
US8442390B2 (en) * 2007-08-29 2013-05-14 Philip Morris Usa Inc. Pulsed aerosol generation
CA2698808A1 (en) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US20090104964A1 (en) * 2007-10-17 2009-04-23 Igt Gaming system, gaming device and gaming method providing player physical activation of the symbol generator
WO2009051782A1 (en) * 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
US20090162421A1 (en) * 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
WO2009097688A1 (en) * 2008-02-05 2009-08-13 Clera Inc. Compositions and methods for alleviating depression or improving cognition
CN101980738A (en) 2008-02-07 2011-02-23 华盛顿大学 Circumferential aerosol device
CA2716788C (en) 2008-02-29 2016-08-16 Concert Pharmaceuticals, Inc. Deuterium-substituted xanthine derivatives
RU2547441C2 (en) 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Boron-containing small molecules as anti-inflammatory agents
US8201752B2 (en) * 2008-03-10 2012-06-19 Vapore, Inc. Low energy vaporization of liquids: apparatus and methods
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US8722079B2 (en) 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US9610243B2 (en) 2008-04-18 2017-04-04 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US9132085B2 (en) 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US9449150B2 (en) 2008-04-24 2016-09-20 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US9662391B2 (en) 2008-04-24 2017-05-30 The Invention Science Fund I Llc Side effect ameliorating combination therapeutic products and systems
US20100017001A1 (en) * 2008-04-24 2010-01-21 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US9282927B2 (en) 2008-04-24 2016-03-15 Invention Science Fund I, Llc Methods and systems for modifying bioactive agent use
US9560967B2 (en) 2008-04-24 2017-02-07 The Invention Science Fund I Llc Systems and apparatus for measuring a bioactive agent effect
US9649469B2 (en) 2008-04-24 2017-05-16 The Invention Science Fund I Llc Methods and systems for presenting a combination treatment
DK2293794T3 (en) * 2008-05-27 2013-08-19 Univ Melbourne Method for treating mammals with dysfunction of the eustachian tube
US7845277B2 (en) * 2008-05-28 2010-12-07 Autoliv Asp, Inc. Header assembly
US20110160253A1 (en) * 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
WO2010019557A1 (en) * 2008-08-12 2010-02-18 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
WO2010024930A2 (en) * 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
US7834295B2 (en) 2008-09-16 2010-11-16 Alexza Pharmaceuticals, Inc. Printable igniters
US20100065052A1 (en) * 2008-09-16 2010-03-18 Alexza Pharmaceuticals, Inc. Heating Units
EP2805950B1 (en) 2008-09-19 2017-11-08 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
EP2364151A1 (en) 2008-10-30 2011-09-14 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
EP3603674A1 (en) 2008-10-30 2020-02-05 Concert Pharmaceuticals, Inc. Combination of morphinan compounds and antidepressant for the treatment of intractable and chronic pain
US8198268B2 (en) * 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
RU2011122647A (en) 2008-11-04 2012-12-20 Энкер Терапьютикс, Инк. CXCR4-RECEPTOR COMPOUNDS
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
WO2010065755A1 (en) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US20100166613A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163024A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Methods and systems for presenting an inhalation experience
US8725529B2 (en) 2008-12-30 2014-05-13 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US20100163038A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US8712794B2 (en) * 2008-12-30 2014-04-29 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US20100168525A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100169260A1 (en) * 2008-12-30 2010-07-01 Searete Llc Methods and systems for presenting an inhalation experience
US20100169259A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100168529A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163036A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163033A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163027A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163025A1 (en) * 2008-12-30 2010-07-01 Searete Llc Methods and systems for presenting an inhalation experience
US8694330B2 (en) * 2008-12-30 2014-04-08 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US8738395B2 (en) * 2008-12-30 2014-05-27 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US8706518B2 (en) * 2008-12-30 2014-04-22 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US20100163034A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100168602A1 (en) * 2008-12-30 2010-07-01 Searete Llc Methods and systems for presenting an inhalation experience
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100234925A1 (en) * 2009-03-16 2010-09-16 PinPoint U.S.A., Inc. Treatment of microbiological pathogens in a toe nail with antimicrobial light
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
CA2835771C (en) * 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2010107761A1 (en) 2009-03-18 2010-09-23 Acelrx Pharmaceuticals, Inc. Improved storage and dispensing devices for administration of oral transmucosal dosage forms
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US20100300433A1 (en) * 2009-05-28 2010-12-02 Alexza Pharmaceuticals, Inc. Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
AU2010260249B2 (en) 2009-06-18 2013-09-05 Concert Pharmaceuticals, Inc. Deuterated isoindoline-1,3-dione derivatives as PDE4 and TNF-alpha inhibitors
JP2012531419A (en) 2009-06-23 2012-12-10 コンサート ファーマシューティカルズ インコーポレイテッド Deuterium-modified triazolopyridazine derivatives as GABA-A receptor modifiers
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
US8617583B2 (en) * 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US8814922B2 (en) * 2009-07-22 2014-08-26 New Star Lasers, Inc. Method for treatment of fingernail and toenail microbial infections using infrared laser heating and low pressure
US8231891B2 (en) * 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US10758582B2 (en) * 2009-08-17 2020-09-01 Xten Capital Group, Inc. Vaporized medicants and methods of use
HUE038136T2 (en) * 2009-09-09 2018-09-28 Sensa Bues Ab Drug detection in exhaled breath
EP3132806B1 (en) 2009-10-13 2022-03-16 Philip Morris Products S.A. Aerosol generator
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
US20110100360A1 (en) * 2009-11-02 2011-05-05 Joseph Dee Faram Composite lung therapy device and method
US9151425B2 (en) * 2009-11-02 2015-10-06 Comedica Incorporated Multiple conduit connector apparatus and method
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2536696A1 (en) 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Pyrimidine derivatives
US9155795B2 (en) 2010-02-26 2015-10-13 Anchor Therapeutics, Inc. CXCR4 receptor compounds
WO2011109464A1 (en) 2010-03-02 2011-09-09 Concert Pharmaceuticals Inc. Deuterated tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2012009446A1 (en) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Novel pyrimidinecarboxamide derivatives
EP2605816B1 (en) * 2010-08-20 2019-01-23 University Of Washington Circumferential aerosol device for delivering drugs to olfactory epithelium and brain
US20120048963A1 (en) 2010-08-26 2012-03-01 Alexza Pharmaceuticals, Inc. Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter
ES2635333T3 (en) 2010-09-07 2017-10-03 Anacor Pharmaceuticals, Inc. Benzoxaborol derivatives to treat bacterial infections
DE102010041840A1 (en) * 2010-10-01 2012-04-05 Bayerische Motoren Werke Aktiengesellschaft Method for producing a ventilation bore in a bearing block of a crankcase of a reciprocating internal combustion engine
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
CA3114582A1 (en) 2010-12-22 2012-06-28 Syqe Medical Ltd. Method and system for drug delivery
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
CA2828884C (en) 2011-03-03 2021-04-27 Impel Neuropharma, Inc. Nasal drug delivery device
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
JP6645735B2 (en) 2011-05-09 2020-02-14 インペル ニューロファーマ インコーポレイテッド Nose delivery nozzle
WO2012154738A1 (en) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition and method to improve intestinal health
WO2012154728A1 (en) 2011-05-10 2012-11-15 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
RS56096B1 (en) 2011-05-18 2017-10-31 Concert Pharmaceuticals Inc Deuterated derivatives of ivacaftor
AU2013208109A1 (en) 2012-01-09 2014-08-14 Anchor Therapeutics, Inc. APJ receptor compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
JP5935877B2 (en) * 2012-03-30 2016-06-15 日本電気株式会社 Flow line data analysis apparatus, system, program and method
AU2013245662A1 (en) 2012-04-13 2014-10-30 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2013159026A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Deuterated rigosertib
WO2013188783A1 (en) 2012-06-15 2013-12-19 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
ES2694202T3 (en) 2012-07-12 2018-12-19 Concert Pharmaceuticals, Inc. Deuterated Idebenone
ES2717279T3 (en) 2012-08-17 2019-06-20 Concert Pharmaceuticals Inc Deuterated baricitinib
EP2711006A1 (en) 2012-09-21 2014-03-26 Basil Rigas Product Comprising a Nicotine-Containing Material and an Anti-Cancer Agent
MY183582A (en) 2012-11-19 2021-02-26 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
US10034988B2 (en) 2012-11-28 2018-07-31 Fontem Holdings I B.V. Methods and devices for compound delivery
US9795752B2 (en) 2012-12-03 2017-10-24 Mhs Care-Innovation, Llc Combination respiratory therapy device, system, and method
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
MX2015008187A (en) 2012-12-20 2016-02-05 Concert Pharmaceuticals Inc Deuterated alk inhibitors.
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US9186860B2 (en) 2013-01-28 2015-11-17 Carl D. Luenser Vaporizer kit for tobacco, medications, and the like
CA2906396A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
EA201892726A1 (en) 2013-03-15 2019-04-30 Консерт Фармасьютикалс, Инк. DEUTERED PALBOCYCLIB
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
HU231191B1 (en) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Isotope containing morphine molecules
JP2016520378A (en) 2013-04-28 2016-07-14 インペル ニューロファーマ インコーポレイテッド Medical unit dose container
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
CN104274427A (en) * 2013-07-03 2015-01-14 陆克塞纳医药公司 Novel aerosol formulations of granisetron and uses thereof
CN104274426A (en) 2013-07-03 2015-01-14 陆克塞纳医药公司 Novel aerosol formulations of ondansetron and uses thereof
ES2821907T3 (en) 2013-07-11 2021-04-28 Alexza Pharmaceuticals Inc Nicotine salt with metasalicylic acid
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
US20160159861A1 (en) 2013-07-18 2016-06-09 Anchor Therapeutics, Inc. APJ Receptor Compounds
MX348595B (en) 2013-08-02 2017-06-21 Laboratorio Raam De Sahuayo S A De C V Pharmaceutical composition with anti-inflammatory agents and production process thereof.
WO2015031741A1 (en) 2013-08-30 2015-03-05 Concert Pharmaceuticals, Inc. Deuterated derivatives of a thienotriazolodiazapine bromodomain-containing protein inhibitor
WO2015042412A1 (en) 2013-09-20 2015-03-26 E-Nicotine Technology. Inc. Devices and methods for modifying delivery devices
US9364815B2 (en) * 2013-11-07 2016-06-14 Saudi Basic Industries Corporation Method of preparing an alumina catalyst support and catalyst for dehydrogenation reactions, and its use
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
IL282010B (en) 2013-12-24 2022-07-01 Univ Virginia Commonwealth Uses of oxygenated cholesterol sulfates
JP6494631B2 (en) 2013-12-24 2019-04-03 プレジデント アンド フェローズ オブ ハーバード カレッジ Colchistatin analogues and their synthesis and use
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
EP4119131A1 (en) 2014-02-20 2023-01-18 Otitopic Inc. Dry powder formulations for inhalation
CN106414122A (en) * 2014-03-10 2017-02-15 老虎工具国际公司 Heating and cooling systems and methods for truck cabs
WO2015148649A2 (en) * 2014-03-26 2015-10-01 Basil Rigas Systems and methods for ameliorating the effects of tobacco products
US20170027963A1 (en) * 2014-04-10 2017-02-02 Patrick Crowley Delivery of non-steroidal agents to the brain via the nasal tract to treat neurological disorders
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
RU2705800C2 (en) 2014-06-06 2019-11-12 Рисерч Трайэнгл Инститьют Apelin receptor agonists (apj) and use thereof
JP2015229527A (en) * 2014-06-09 2015-12-21 三光機械株式会社 Multi-row type automatic packing machine
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
KR20230117250A (en) 2014-06-30 2023-08-07 사이키 메디컬 엘티디. Drug dose cartridge for an inhaler device
IL273507B1 (en) 2014-06-30 2024-02-01 Syqe Medical Ltd Methods, devices and systems for pulmonary delivery of active agents
AU2015283589B2 (en) 2014-06-30 2019-09-12 Syqe Medical Ltd. Method and device for vaporization and inhalation of isolated substances
CA2953082C (en) 2014-06-30 2023-07-11 Syqe Medical Ltd. Flow regulating inhaler device
EP3160565B1 (en) 2014-06-30 2021-08-18 Syqe Medical Ltd. Devices and systems for pulmonary delivery of active agents
EP3961640A1 (en) 2014-09-29 2022-03-02 Zogenix International Limited Control system for control of distribution of medication
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016106329A1 (en) 2014-12-23 2016-06-30 Acelrx Pharmaceuticals, Inc. Systems, devices and methods for dispensing oral transmucosal dosage forms
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
US20160206610A1 (en) * 2015-01-20 2016-07-21 Xoc Pharmaceuticals, Inc. Methods for treating and/or preventing emesis and/or nausea including acute and/or delayed nausea and/or acute emesis and/or delayed emesis
JP6856532B2 (en) 2015-01-20 2021-04-07 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ Ergoline compounds and their use
US9676776B2 (en) 2015-01-20 2017-06-13 Xoc Pharmaceuticals, Inc. Isoergoline compounds and uses thereof
EP3265440A1 (en) 2015-03-06 2018-01-10 Concert Pharmaceuticals Inc. Deuterated emricasan
CN107750177B (en) 2015-03-11 2022-03-11 艾利斯达医药品公司 Use of antistatic materials in airways for hot aerosol condensation processes
AU2016243171B2 (en) 2015-03-31 2020-10-08 Concert Pharmaceuticals, Inc. Deuterated VX-661
WO2016159889A1 (en) 2015-04-02 2016-10-06 Hill-Rom Services Pte. Ltd. Manifold for respiratory device
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316883A4 (en) * 2015-06-30 2019-06-12 University of South Florida Inhibitors of the fkbp51 protein from a high-throughput drug screen and methods of use
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017004501A1 (en) 2015-07-02 2017-01-05 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
US20180243289A1 (en) 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
US11266799B2 (en) 2015-09-10 2022-03-08 Impel Neuropharma, Inc. In-line nasal delivery device
US11267777B2 (en) 2015-11-19 2022-03-08 Concert Pharmaceuticals, Inc. Deuterated EPI-743
BR112018011784A2 (en) 2015-12-09 2018-12-04 Res Triangle Inst improved apelin receptor (apj) agonists and their uses
CA3007673A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
MX2021000482A (en) * 2015-12-22 2022-03-29 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same.
US10092036B2 (en) * 2015-12-28 2018-10-09 Rai Strategic Holdings, Inc. Aerosol delivery device including a housing and a coupler
CA3009599A1 (en) 2016-01-06 2017-07-13 Syqe Medical Ltd. Low dose therapeutic treatment
RU2768748C2 (en) 2016-02-01 2022-03-24 Инкарда Терапьютикс, Инк. Combination of electronic monitoring with inhalation pharmacological therapy for control of cardiac arrhythmias, including atrial fibrillation
US20170216220A1 (en) * 2016-02-03 2017-08-03 Intelgenx Corp. Loxapine film oral dosage form
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
WO2017218796A1 (en) 2016-06-15 2017-12-21 Ott Harald C Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions
KR20230017361A (en) 2016-07-04 2023-02-03 아바니르 파마슈티컬스, 인코포레이티드 Methods for the synthesis of deuterated dextromethorphan
KR102511953B1 (en) 2016-08-01 2023-03-20 더 브리검 앤드 우먼즈 하스피털, 인크. Particles for protein and peptide delivery
RU2746000C2 (en) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Composition for inhibiting synthesis of 5-ht2b agonist and methods of use thereof
DE102016221705B4 (en) 2016-11-07 2018-05-17 Schaeffler Technologies AG & Co. KG Gear from a gear assembly and method for producing a gear assembly
US20180185347A1 (en) * 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
JP7379154B2 (en) 2016-12-09 2023-11-14 アレクザ・ファーマシューティカルズ・インコーポレイテッド How to treat epilepsy
HUE050829T2 (en) 2017-02-02 2021-01-28 Otolanum Ag Intranasal composition comprising betahistine
JP7152408B2 (en) 2017-03-10 2022-10-12 キアペグ ファーマシューティカルズ アクチエボラグ releasable conjugate
US20200129504A1 (en) 2017-03-13 2020-04-30 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof
CA3060702A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2018270266B2 (en) 2017-05-19 2022-06-30 Superb Wisdom Limited Derivatives of resiquimod
CA3064274A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
US20210137898A1 (en) 2017-06-15 2021-05-13 Mayo Foundation For Medical Education And Research Methods to treat gliomas using a stat3 inhibitor
US11396516B2 (en) 2017-06-16 2022-07-26 The General Hospital Corporation Tricyclic compounds as Cyp1 inhibitors
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
CN109391578B (en) * 2017-08-11 2022-07-22 华为技术有限公司 Signal sending method, signal receiving method, terminal equipment and network equipment
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US11224608B2 (en) 2017-10-16 2022-01-18 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
US11395887B2 (en) 2017-11-21 2022-07-26 Impel Pharmaceuticals Inc. Intranasal device with inlet interface
JP7191099B2 (en) 2017-11-21 2022-12-16 インペル ファーマシューティカルズ インコーポレイテッド intranasal device with dip tube
RU2020125871A (en) 2018-01-05 2022-02-07 Импел Ньюрофарма, Инк. INTRANASAL DELIVERY OF DIHYDROERGOTAMINE USING A PRECISION DELIVERY DEVICE TO THE OLFACTORY REGION
US11278492B2 (en) 2018-01-05 2022-03-22 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
US20210038561A1 (en) 2018-01-31 2021-02-11 Mayo Foundation For Medical Education And Research Methods of treating fibrotic pathologies
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
CA3079509C (en) 2018-07-04 2020-11-03 AMEZCUA AMEZCUA, Federico Synergic drug combination of the active enantiomer (s)-ketorolac and gabapentin for the treatment of neuropathic pain
CN112654349A (en) 2018-07-05 2021-04-13 梅约医学教育与研究基金会 PIKfyve inhibitors
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease
US20210228598A1 (en) 2018-08-13 2021-07-29 Federico Amezcua Amezcua Synergistic pharmaceutical composition comprising aceclofenac and betamethasone for the treatment of pain in localised forms of rheumatic illnesses
US11090449B2 (en) 2018-08-21 2021-08-17 Vivera Pharmaceuticals Inc. Smart inhaler device with automated dose delivery, measurement, and management
US11083850B2 (en) 2018-08-21 2021-08-10 Vivera Pharmaceuticals Inc. Secure smart dosing system with automated delivery, measurement, and management
CA3112473A1 (en) 2018-09-12 2020-03-19 Quiapeg Pharmaceuticals Ab Releasable glp-1 conjugates
KR20210111787A (en) 2019-01-03 2021-09-13 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Methods and materials for increasing transcription factor EB polypeptide levels
AU2019418744B2 (en) 2019-01-03 2023-08-03 Impel Pharmaceuticals Inc. Nasal drug delivery device
MX2019000312A (en) 2019-01-08 2019-10-09 Federico Amezcua Amezcua A synergistic pharmaceutical composition of aceclofenac and betamethasone for the treatment of pain of rheumatic affections or post-surgical pain.
CN109674773A (en) * 2019-02-22 2019-04-26 南京中医药大学 A kind of 'Xiduofeng ' drug microparticles of pulmonary administration and the preparation method and application thereof
BR112021023049A8 (en) 2019-05-17 2022-10-18 Impel Neuropharma Inc SINGLE USE NASAL DISPENSING DEVICE
EP4003348B1 (en) 2019-07-30 2024-04-03 Mayo Foundation for Medical Education and Research Compounds and methods for treating fibrotic pathologies
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US11364225B2 (en) 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
MX2022003189A (en) 2019-09-16 2022-06-08 Vapor Cartridge Tech Llc Drug delivery system with stackable substrates.
EP3868364A1 (en) 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
US20220117916A1 (en) * 2020-10-19 2022-04-21 SafeRx Pharmaceuticals, LLC Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose
EP4159192A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
TW202325285A (en) * 2021-10-14 2023-07-01 靜岡縣公立大學法人 Powder drug formulation
IT202100031637A1 (en) 2021-12-17 2023-06-17 Universita’ Degli Studi Di Parma DUST FOR INHALATION AND PRODUCTION PROCEDURE
EP4349175A1 (en) 2022-10-05 2024-04-10 The Procter & Gamble Company Antimicrobial composition comprising a modified alkyl glycoside and an organic acid

Family Cites Families (273)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58009A (en) * 1866-09-11 Improved condenser
US30285A (en) * 1860-10-09 Fruit-drier
US113557A (en) * 1871-04-11 Improvement in metal screws and nuts
US32638A (en) * 1861-06-25 Boot-heel
GB502761A (en) 1938-01-29 1939-03-24 Christopher Engelbreth Improvements in and relating to hand inhalation apparatus
US2902484A (en) 1954-04-27 1959-09-01 Rhone Poulenc Sa Phenthiazine derivatives and processes for their preparation
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
BE623427A (en) 1961-10-10
GB972363A (en) 1962-08-18 1964-10-14 Rambold Adolf Wrapper band for teabag or the like
US3169095A (en) 1962-10-30 1965-02-09 Rexall Drug Chemical Self-propelling powder-dispensing compositions
NL289785A (en) 1962-11-29
GB1063512A (en) 1962-11-30 1967-03-30 Benger Lab Ltd Aerosols
US3456247A (en) * 1966-01-14 1969-07-15 Ibm Coupled film storage device
IL26896A (en) 1966-01-19 1970-11-30 Endo Lab 14-hydroxynormorphines and 14-hydroxynormorphinones
US3987052A (en) 1969-03-17 1976-10-19 The Upjohn Company 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines
USRE30285E (en) 1972-05-22 1980-05-27 Spraying devices, in particular nebulizing devices
US3949743A (en) * 1973-03-19 1976-04-13 Schick Incorporated Medicated vapor production method and apparatus
US3982095A (en) 1973-10-04 1976-09-21 Searle Cardio-Pulmonary Systems Inc. Respiratory humidifier
US3894040A (en) 1974-09-16 1975-07-08 American Home Prod 2,5,6,7-Tetrahydro-3H-imidazo(1,2-D)(1,4)benzodiazepine-5,6-dicarboxylic acid esters
US4121583A (en) 1976-07-13 1978-10-24 Wen Yuan Chen Method and apparatus for alleviating asthma attacks
US4141369A (en) 1977-01-24 1979-02-27 Burruss Robert P Noncombustion system for the utilization of tobacco and other smoking materials
SE7812207L (en) 1977-12-01 1979-06-02 Welsh Nat School Med APPARATUS, PROCEDURE AND MANUFACTURED PRODUCTS FOR USE IN THE ADMINISTRATION OF ANTIHISTAMINES
US4183912A (en) 1978-01-16 1980-01-15 American Home Products Corporation Inhalation therapy for relieving bronchial spasm using quaternary salts of promethazine
US4484451A (en) * 1978-09-05 1984-11-27 United Air Specialists, Inc. Two-stage gas condenser with feedback cooling
IL59407A (en) 1979-03-06 1983-12-30 Sanofi Sa Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them
US4654370A (en) 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
ATE3774T1 (en) 1980-05-02 1983-06-15 Schering Corporation BECLOMETHASONE ESTER SOLVATE, PROCESS FOR THEIR PREPARATION AND PREPARATION OF A FORMULATION.
US4303083A (en) 1980-10-10 1981-12-01 Burruss Jr Robert P Device for evaporation and inhalation of volatile compounds and medications
US4376767A (en) 1981-01-02 1983-03-15 Merck & Co., Inc. Pyridylmethyl esters of selected bio-affecting carboxylic acids
DE3116951C2 (en) 1981-04-29 1984-12-20 Drägerwerk AG, 2400 Lübeck Device for adding liquid anesthetics to the breathing gas to be supplied to the patient
DE3224849A1 (en) 1982-07-02 1984-01-05 Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn STEAM INHALER
US4508726A (en) 1982-09-16 1985-04-02 The Upjohn Company Treatment of panic disorders with alprazolam
US4474191A (en) 1982-09-30 1984-10-02 Steiner Pierre G Tar-free smoking devices
AT398259B (en) 1982-09-30 1994-11-25 Dainippon Jochugiku Kk THERMAL SMOKER FOR A CHEMICAL PREPARATION
US4753758A (en) 1983-05-19 1988-06-28 Intertech Resources Inc. Respiratory humidifier
DE3326089A1 (en) 1983-07-20 1985-02-07 Gödecke AG, 1000 Berlin INHALATION-INTENDED PHARMACEUTICAL FORM OF CALCIUM ANTAGONISTS
DE3476197D1 (en) 1983-08-01 1989-02-23 Mclean Hospital Corp Gaba esters and gaba analogue esters
US4588721A (en) 1983-09-12 1986-05-13 The Upjohn Company Treatment of negative symptoms of schizophrenia
US4566552A (en) * 1983-11-16 1986-01-28 International Harvester Company Hood tilt retardation system
US4683231A (en) 1984-03-02 1987-07-28 Research Foundation For Mental Hygiene, Inc. Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking
US4793365A (en) 1984-09-14 1988-12-27 R. J. Reynolds Tobacco Company Smoking article
US5042509A (en) 1984-09-14 1991-08-27 R. J. Reynolds Tobacco Company Method for making aerosol generating cartridge
US5067499A (en) 1984-09-14 1991-11-26 R. J. Reynolds Tobacco Company Smoking article
US5020548A (en) 1985-08-26 1991-06-04 R. J. Reynolds Tobacco Company Smoking article with improved fuel element
US4854331A (en) 1984-09-14 1989-08-08 R. J. Reynolds Tobacco Company Smoking article
CN1018607B (en) 1984-12-21 1992-10-14 美国耳·杰·瑞诺兹烟草公司 Smoking article
US4928714A (en) 1985-04-15 1990-05-29 R. J. Reynolds Tobacco Company Smoking article with embedded substrate
ATE78158T1 (en) 1985-05-22 1992-08-15 Liposome Technology Inc METHOD AND SYSTEM FOR INHALATION OF LIPOSOMES.
US4989619A (en) 1985-08-26 1991-02-05 R. J. Reynolds Tobacco Company Smoking article with improved fuel element
US4756318A (en) 1985-10-28 1988-07-12 R. J. Reynolds Tobacco Company Smoking article with tobacco jacket
US5060666A (en) 1985-10-28 1991-10-29 R. J. Reynolds Tobacco Company Smoking article with tobacco jacket
US5033483A (en) 1985-10-28 1991-07-23 R. J. Reynolds Tobacco Company Smoking article with tobacco jacket
JPS62204756A (en) * 1986-03-04 1987-09-09 大研医工株式会社 Drug volatilizing method and apparatus
EP0259383B1 (en) 1986-03-10 1991-01-23 Kurt Dr. Burghart Pharmaceutical preparation and process for preparing the same
US4708151A (en) 1986-03-14 1987-11-24 R. J. Reynolds Tobacco Company Pipe with replaceable cartridge
US4771795A (en) 1986-05-15 1988-09-20 R. J. Reynolds Tobacco Company Smoking article with dual burn rate fuel element
US4917120A (en) 1986-05-21 1990-04-17 Advanced Tobacco Products, Inc. Nicotine impact modification
US4735217A (en) * 1986-08-21 1988-04-05 The Procter & Gamble Company Dosing device to provide vaporized medicament to the lungs as a fine aerosol
US4858630A (en) 1986-12-08 1989-08-22 R. J. Reynolds Tobacco Company Smoking article with improved aerosol forming substrate
US4734560A (en) 1987-01-20 1988-03-29 Medical Enterprises, Ltd. Vaporizing unit
US4819665A (en) 1987-01-23 1989-04-11 R. J. Reynolds Tobacco Company Aerosol delivery article
US4924883A (en) 1987-03-06 1990-05-15 R. J. Reynolds Tobacco Company Smoking article
US5017575A (en) 1987-06-09 1991-05-21 Golwyn Daniel H Treatment of immunologically based disorders, specifically Crohn's disease
GB8713645D0 (en) 1987-06-11 1987-07-15 Imp Tobacco Ltd Smoking device
US5019122A (en) 1987-08-21 1991-05-28 R. J. Reynolds Tobacco Company Smoking article with an enclosed heat conductive capsule containing an aerosol forming substance
US4906417A (en) 1988-02-08 1990-03-06 Associated Mills Inc. Humidifier
US4853517A (en) 1988-03-28 1989-08-01 John G. Bowen Vaporizing unit
US4906119A (en) * 1988-04-14 1990-03-06 Lloyd Hartford Handwriting stabilizer
DE3815221C2 (en) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli
US4881556A (en) 1988-06-06 1989-11-21 R. J. Reynolds Tobacco Company Low CO smoking article
US5345951A (en) 1988-07-22 1994-09-13 Philip Morris Incorporated Smoking article
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US4947875A (en) 1988-09-08 1990-08-14 R. J. Reynolds Tobacco Company Flavor delivery articles utilizing electrical energy
US4947874A (en) 1988-09-08 1990-08-14 R. J. Reynolds Tobacco Company Smoking articles utilizing electrical energy
EP0358114A3 (en) 1988-09-08 1990-11-14 R.J. Reynolds Tobacco Company Aerosol delivery articles utilizing electrical energy
USRE36744E (en) 1988-09-16 2000-06-20 Ribogene, Inc. Nasal administration of benzodiazepine hypnotics
US4950664A (en) 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
US4963289A (en) * 1988-09-19 1990-10-16 The United States Of America As Represented By The United States Department Of Energy Method for producing monodisperse aerosols
US5511726A (en) * 1988-09-23 1996-04-30 Battelle Memorial Institute Nebulizer device
US4917119A (en) 1988-11-30 1990-04-17 R. J. Reynolds Tobacco Company Drug delivery article
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
DE3908161A1 (en) 1989-03-13 1990-09-27 Bat Cigarettenfab Gmbh Smokable article
JP3062760B2 (en) * 1989-03-14 2000-07-12 コニカ株式会社 Compound lens
EP0705614B1 (en) 1989-04-28 2002-09-25 Riker Laboratories, Inc. Dry powder inhalation device
ATE140868T1 (en) 1989-05-05 1996-08-15 North Sydney Area Health Serv INCREASE FERTILITY
ES2046368T3 (en) * 1989-05-17 1994-02-01 Leifeld Gmbh & Co. PROCEDURE FOR THE MANUFACTURE OF A PULLEY.
US4941483A (en) 1989-09-18 1990-07-17 R. J. Reynolds Tobacco Company Aerosol delivery article
US6313176B1 (en) 1989-10-17 2001-11-06 Everett J. Ellinwood, Jr. Dosing method of administering deprenyl via intraoral administration or inhalation administration
US6048857A (en) 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5060671A (en) 1989-12-01 1991-10-29 Philip Morris Incorporated Flavor generating article
US5224498A (en) * 1989-12-01 1993-07-06 Philip Morris Incorporated Electrically-powered heating element
US5144962A (en) 1989-12-01 1992-09-08 Philip Morris Incorporated Flavor-delivery article
WO1991007947A1 (en) 1989-12-05 1991-06-13 Ramsey Foundation Neurologic agents for nasal administration to the brain
GB2239807A (en) 1990-01-09 1991-07-17 Boc Group Plc Anaesthetic vaporiser
US5376386A (en) 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5099861A (en) 1990-02-27 1992-03-31 R. J. Reynolds Tobacco Company Aerosol delivery article
US5366770A (en) 1990-04-17 1994-11-22 Xingwu Wang Aerosol-plasma deposition of films for electronic cells
US5455043A (en) 1990-06-13 1995-10-03 Fischel-Ghodsian; Fariba Device for controlled release of vaporous medications through nasal route
US5126123A (en) 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
EP0469797B2 (en) 1990-08-02 2001-12-12 Datex-Ohmeda Inc. Anaesthetic vaporiser
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5166202A (en) 1990-09-19 1992-11-24 Trustees Of The University Of Pennsylvania Method for the treatment of panic disorder
US5343226A (en) * 1990-09-28 1994-08-30 Dataproducts Corporation Ink jet ink supply apparatus
US5175152A (en) 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
DE69229070T2 (en) 1991-02-09 1999-11-18 B S D Bio Science Dev Snc Di O Antireactive anti-asthmatic effects of acetylsalicylic acid by inhalation
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5457100A (en) 1991-12-02 1995-10-10 Daniel; David G. Method for treatment of recurrent paroxysmal neuropsychiatric
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5622944A (en) 1992-06-12 1997-04-22 Affymax Technologies N.V. Testosterone prodrugs for improved drug delivery
KR100208979B1 (en) 1992-06-12 1999-07-15 야스이 쇼사꾸 Pharmaceutical preparation for intra-airway administration
US5284133A (en) * 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
WO1994009842A1 (en) * 1992-10-28 1994-05-11 Rosen Charles A Method and devices for delivering drugs by inhalation
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5507277A (en) 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
US5915378A (en) 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5694919A (en) 1993-01-29 1997-12-09 Aradigm Corporation Lockout device for controlled release of drug from patient-activated dispenser
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5724957A (en) 1993-01-29 1998-03-10 Aradigm Corporation Intrapulmonary delivery of narcotics
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5357257A (en) * 1993-04-05 1994-10-18 General Electric Company Apparatus and method for equalizing channels in a multi-channel communication system
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5666977A (en) * 1993-06-10 1997-09-16 Philip Morris Incorporated Electrical smoking article using liquid tobacco flavor medium delivery system
JP3553599B2 (en) 1993-06-29 2004-08-11 インジェット ディジタル エアロソルズ リミテッド dispenser
US5388574A (en) 1993-07-29 1995-02-14 Ingebrethsen; Bradley J. Aerosol delivery article
DE4328243C1 (en) 1993-08-19 1995-03-09 Sven Mielordt Smoke or inhalation device
US5456247A (en) 1993-08-26 1995-10-10 Iowa State University Research Foundation, Inc. Method for delivering drugs soluble in a vaporization vehicle
FI98270C (en) 1993-11-29 1997-05-26 Instrumentarium Oy Method and apparatus for evaporation of anesthetic agent
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5451408A (en) 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs
US6102036A (en) 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
CA2189351C (en) 1994-05-13 2008-12-30 Stephen J. Farr Narcotic containing aerosol formulation
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
WO1996011689A1 (en) 1994-10-14 1996-04-25 Glaxo Wellcome Spa Use of cck-b receptor antagonists for the treatment of sleep disorders
EP0788387A4 (en) 1994-10-28 1998-07-08 Aradigm Corp Device and method of creating aerosolized mist of respiratory drug
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
CA2216443A1 (en) 1995-03-31 1996-10-03 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
US5758637A (en) 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
DE19519056A1 (en) 1995-05-24 1997-01-16 Klinge Co Chem Pharm Fab Use of antidepressants for the treatment of asthma and / or respiratory diseases by inhalation
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
JPH0943487A (en) 1995-08-01 1997-02-14 Fuji Photo Film Co Ltd Zoom lens
US5649554A (en) 1995-10-16 1997-07-22 Philip Morris Incorporated Electrical lighter with a rotatable tobacco supply
AU7669496A (en) 1995-11-03 1997-05-22 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US5564442A (en) 1995-11-22 1996-10-15 Angus Collingwood MacDonald Battery powered nicotine vaporizer
US6041777A (en) * 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
ATE263546T1 (en) 1995-12-14 2004-04-15 Taisho Pharmaceutical Co Ltd AEROSOL PREPARATION
SE9504580L (en) 1995-12-21 1997-06-22 Siemens Elema Ab Procedure for gasification of an anesthetic fluid and a carburetor
EP0955885A1 (en) 1996-02-05 1999-11-17 Aradigm Corporation Ventilation imaging using a fine particle aerosol generator
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5927124A (en) * 1996-03-05 1999-07-27 Adaptive Motion Control Systems, Inc. Apparatus for bending and cutting tubing, and method of using same
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
CZ343798A3 (en) * 1996-04-29 1999-02-17 Dura Pharmaceuticals, Inc. Inhaling system for inhaling dry powder
US5743251A (en) 1996-05-15 1998-04-28 Philip Morris Incorporated Aerosol and a method and apparatus for generating an aerosol
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
GB9613015D0 (en) 1996-06-21 1996-08-28 Reckitt & Colman Inc Device
IL127955A0 (en) 1996-07-11 1999-11-30 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
US6694975B2 (en) * 1996-11-21 2004-02-24 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
ES2236832T3 (en) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology PREPARATION OF PARTICLES FOR INHALATION.
DK1014943T3 (en) 1997-02-05 2002-10-14 Jago Res Ag Medical aerosol formulations
US5829435A (en) 1997-02-24 1998-11-03 Aradigm Corporation Prefilter for prevention of clogging of a nozzle in the generation of an aerosol and prevention of administration of undesirable particles
US5837713A (en) 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
KR100289448B1 (en) 1997-07-23 2001-05-02 미즈노 마사루 Flavor generator
US5874841A (en) * 1997-07-28 1999-02-23 Philips Electronics North America Corporation Sample-and-hold circuit for a switched-mode power supply
US6090212A (en) 1997-08-15 2000-07-18 Micro C Technologies, Inc. Substrate platform for a semiconductor substrate during rapid high temperature processing and method of supporting a substrate
DK1019022T4 (en) 1997-09-29 2010-11-08 Novartis Ag Perforated microparticles and their method of use
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US5915841A (en) * 1998-01-05 1999-06-29 Capstone Turbine Corporation Compliant foil fluid film radial bearing
US20020006181A1 (en) 1998-01-23 2002-01-17 Mackenzie Innes K. Method and device for estimating bone mineral content of the calcaneus
US6158431A (en) 1998-02-13 2000-12-12 Tsi Incorporated Portable systems and methods for delivery of therapeutic material to the pulmonary system
CA2322805C (en) 1998-03-05 2005-09-13 Nippon Shinyaku Co., Ltd. Fat emulsions for inhalational administration
HUP0101627A3 (en) 1998-04-14 2003-02-28 Gen Hospital Corp Boston Pharmaceutical compositions for treating neuropsychiatric disorders
EP1083951A4 (en) 1998-06-12 2004-07-07 Aradigm Corp Methods of delivering aerosolized polynucleotides to the respiratory tract
US6095153A (en) 1998-06-19 2000-08-01 Kessler; Stephen B. Vaporization of volatile materials
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
WO2000000215A1 (en) 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
MA25590A1 (en) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst ACTIVE AGENT FOR DRY POWDER DELIVERY
US6234167B1 (en) 1998-10-14 2001-05-22 Chrysalis Technologies, Incorporated Aerosol generator and methods of making and using an aerosol generator
US6509005B1 (en) 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
US6255334B1 (en) * 1998-10-30 2001-07-03 Pfizer Inc 5HT 1 receptor agonists and metoclopramide for the treatment of migraine
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
JP2002529393A (en) 1998-11-12 2002-09-10 フランク ジー． ピルキーウィッツ， Inhalation system
CZ303154B6 (en) 1998-11-13 2012-05-09 Jagotec Ag Dry powder formulation for inhalation containing magnesium stearate
US6070575A (en) 1998-11-16 2000-06-06 Aradigm Corporation Aerosol-forming porous membrane with certain pore structure
DE69818872T2 (en) * 1998-12-11 2004-05-19 Pharmachemie B.V. PHARMACEUTICAL PREPARATIONS FOR INHALATION OF AN OPIOID
US6376550B1 (en) 1999-02-09 2002-04-23 Asta Medica Ag Pharmaceutical compositions containing tramadol for migraine
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
US6591839B2 (en) * 1999-02-17 2003-07-15 Dieter Meyer Filter material for reducing harmful substances in tobacco smoke
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
CA2370302A1 (en) 1999-04-27 2000-11-02 Benjamin Lee Hughes Insulin crystals for pulmonary administration
ATE274955T1 (en) 1999-05-03 2004-09-15 Battelle Memorial Institute MEDICINAL COMPOSITIONS FOR AEROSOL FORMATION AND INHALATION PURPOSES
US6428769B1 (en) 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
GB9912356D0 (en) * 1999-05-26 1999-07-28 Btg Int Ltd Generation of microfoam
JP4722295B2 (en) 1999-05-27 2011-07-13 エイカスフィアー・インコーポレーテッド Porous drug matrix and method for producing the same
ES2424713T4 (en) 1999-06-11 2014-01-23 Aradigm Corporation Method of producing a spray
US20020061281A1 (en) 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
EP1218048A4 (en) 1999-07-16 2009-08-26 Aradigm Corp System for effecting smoke cessation
MXPA02001568A (en) * 1999-08-13 2002-07-02 Vela Pharmaceuticals Inc Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof.
EP1210121A2 (en) 1999-08-24 2002-06-05 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
WO2001017614A2 (en) 1999-09-07 2001-03-15 Conjuchem, Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
KR20020043223A (en) * 1999-09-30 2002-06-08 해피 페너 ; 해리 에이치. 페너 2세 Certain alkylene diamine-substituted heterocycles
WO2001028354A1 (en) * 1999-10-19 2001-04-26 Agromedic Co., Ltd. Method of feeding reproductive female pigs and feeds for reproductive female pigs
TWI310688B (en) 1999-10-29 2009-06-11 Nektar Therapeutics Dry powder compositions having improved dispersivity
WO2001041732A1 (en) 1999-12-06 2001-06-14 Gore Stanley L Compositions and methods for intranasal delivery of active agents to the brain
US6853310B2 (en) * 1999-12-29 2005-02-08 Ge Medical Systems Information Technologies, Inc. Tri-mode medical telemetry antenna system
ES2305057T3 (en) * 2000-02-28 2008-11-01 Pharmakodex Limited DEVICE FOR THE ADMINISTRATION OF ORAL PHARMACES.
CA2405419A1 (en) * 2000-04-07 2001-10-18 Tap Pharmaceutical Products Inc. Apomorphine derivatives and methods for their use
US6632047B2 (en) 2000-04-14 2003-10-14 Board Of Regents, The University Of Texas System Heater element for use in an in situ thermal desorption soil remediation system
MY136453A (en) * 2000-04-27 2008-10-31 Philip Morris Usa Inc "improved method and apparatus for generating an aerosol"
WO2001093846A2 (en) 2000-05-23 2001-12-13 The Trustees Of Columbia University In The City Of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans
WO2001095903A1 (en) 2000-06-15 2001-12-20 Respiratorius Ab 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
GB0015981D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
FR2812545B1 (en) 2000-08-03 2003-03-28 Air Liquide Sante Int INHALABLE DRUG AEROSOL FOR TREATMENT OR PREVENTION OF SWEETNESS
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
AU2002246500A1 (en) * 2000-10-27 2002-07-30 Emlin Biosciences Thermal vaporizing device for drug delivery
US20020176841A1 (en) * 2001-03-19 2002-11-28 Praecis Pharmaceuticals Inc. Pharmaceutical formulations for sustained release
US20030004142A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
US7645442B2 (en) * 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7585493B2 (en) * 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US6759029B2 (en) 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US20070122353A1 (en) * 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
JP4357842B2 (en) * 2001-05-24 2009-11-04 アレックザ ファーマシューティカルズ， インコーポレイテッド Delivery of alprazolam, estazolam, midazolam or triazolam by a prescribed inhalation route
US7766013B2 (en) * 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
JP2005503425A (en) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション Delivery of drug ester by the prescribed inhalation route
US7498019B2 (en) * 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
EP1392260A2 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of benzodiazepines through an inhalation route
US20030118512A1 (en) * 2001-10-30 2003-06-26 Shen William W. Volatilization of a drug from an inclusion complex
US7458374B2 (en) * 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20030138508A1 (en) * 2001-12-18 2003-07-24 Novack Gary D. Method for administering an analgesic
US20080038363A1 (en) * 2001-05-24 2008-02-14 Zaffaroni Alejandro C Aerosol delivery system and uses thereof
EP1455875A2 (en) * 2001-11-21 2004-09-15 Alexza Molecular Delivery Corporation Open-celled substrates for drug delivery
WO2003057188A1 (en) * 2001-11-21 2003-07-17 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
US6701922B2 (en) * 2001-12-20 2004-03-09 Chrysalis Technologies Incorporated Mouthpiece entrainment airflow control for aerosol generators
US6772756B2 (en) 2002-02-09 2004-08-10 Advanced Inhalation Revolutions Inc. Method and system for vaporization of a substance
EP1503744A1 (en) * 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US20060193788A1 (en) * 2002-11-26 2006-08-31 Hale Ron L Acute treatment of headache with phenothiazine antipsychotics
US7074806B2 (en) * 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7485143B2 (en) * 2002-11-15 2009-02-03 Abbott Cardiovascular Systems Inc. Apparatuses and methods for heart valve repair
KR100459905B1 (en) * 2002-11-21 2004-12-03 삼성전자주식회사 Monolithic inkjet printhead having heater disposed between dual ink chamber and method of manufacturing thereof
JP2006514633A (en) * 2002-11-26 2006-05-11 アレックザ ファーマシューティカルズ， インコーポレイテッド Treatment of headache with antipsychotics delivered by inhalation
CA2507159A1 (en) * 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) * 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
JP4601619B2 (en) * 2003-05-21 2010-12-22 アレックザ ファーマシューティカルズ， インコーポレイテッド Built-in heating unit and medicine supply unit using the same
US20050037506A1 (en) * 2003-08-04 2005-02-17 Alexza Molecular Delivery Corporation Methods of determining film thicknesses for an aerosol delivery article
JP4869927B2 (en) * 2003-08-04 2012-02-08 アレックザ ファーマシューティカルズ， インコーポレイテッド Substrates and preparation methods and uses for drug delivery devices
EP1703932A1 (en) * 2003-12-15 2006-09-27 Alexza Molecular Delivery Corporation Treatment of breakthrough pain by drug aerosol inhalation
WO2005059804A2 (en) * 2003-12-16 2005-06-30 Alexza Pharmaceuticals, Inc. Methods for monitoring severity of panic attacks and other rapidly evolving medical events in real-time
US7402777B2 (en) 2004-05-20 2008-07-22 Alexza Pharmaceuticals, Inc. Stable initiator compositions and igniters
US7540286B2 (en) * 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20060032496A1 (en) * 2004-08-12 2006-02-16 Alexza Molecular Delivery Corporation Inhalation actuated percussive ignition system
EP2246086A3 (en) * 2004-08-12 2012-11-21 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heating unit
US20060120962A1 (en) * 2004-10-12 2006-06-08 Rabinowitz Joshua D Cardiac safe, rapid medication delivery
US7524848B2 (en) * 2006-03-23 2009-04-28 Amgen Inc. Diaza heterocyclic amide compounds and their uses
WO2008080170A1 (en) 2006-12-22 2008-07-03 Alexza Pharmaceuticals, Inc. Mixed drug aerosol compositiions
ES2594867T3 (en) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US20080306285A1 (en) 2007-04-27 2008-12-11 Alexza Pharmaceuticals, Inc. Heat-Labile Prodrugs

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082369A1 (en) * 2003-02-28 2005-09-09 Delex Therapeutics Inc. Opioid delivery system
JP2006519185A (en) * 2003-02-28 2006-08-24 デレックス・セラピューティクス・インコーポレイテッド Opioid delivery system
US7648982B2 (en) 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US7648981B2 (en) 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system

Also Published As

Publication number Publication date
JP2004532860A (en) 2004-10-28
US20040184998A1 (en) 2004-09-23
ATE462420T1 (en) 2010-04-15
CA2447166C (en) 2009-12-22
EP1392259B1 (en) 2007-06-27
PL363996A1 (en) 2004-11-29
US20040127481A1 (en) 2004-07-01
US7014841B2 (en) 2006-03-21
EP1389096B9 (en) 2009-08-26
AU2002303833B2 (en) 2007-11-29
EP1389097A1 (en) 2004-02-18
US7988952B2 (en) 2011-08-02
US20040184996A1 (en) 2004-09-23
US7465435B2 (en) 2008-12-16
CA2446916C (en) 2009-12-22
EP1392264B1 (en) 2008-07-16
US7442368B2 (en) 2008-10-28
EP1389096B1 (en) 2009-03-18
US7078019B2 (en) 2006-07-18
NZ529419A (en) 2006-11-30
US20040184997A1 (en) 2004-09-23
ES2341392T3 (en) 2010-06-18
US20080175796A1 (en) 2008-07-24
DE60235851D1 (en) 2010-05-12
ATE404184T1 (en) 2008-08-15
US20030007934A1 (en) 2003-01-09
MXPA03010702A (en) 2004-03-02
US20030012740A1 (en) 2003-01-16
US20040191184A1 (en) 2004-09-30
US6743415B2 (en) 2004-06-01
US6740308B2 (en) 2004-05-25
US20030005924A1 (en) 2003-01-09
US20060280692A1 (en) 2006-12-14
US20030021754A1 (en) 2003-01-30
MXPA03010703A (en) 2004-07-01
CA2447166A1 (en) 2002-11-28
CA2446904A1 (en) 2003-04-03
US7052679B2 (en) 2006-05-30
US20030017120A1 (en) 2003-01-23
ATE404173T1 (en) 2008-08-15
US20040191179A1 (en) 2004-09-30
ES2311607T3 (en) 2009-02-16
US20060246012A1 (en) 2006-11-02
US6994843B2 (en) 2006-02-07
US7029658B2 (en) 2006-04-18
US7465437B2 (en) 2008-12-16
US6740309B2 (en) 2004-05-25
WO2002094236A9 (en) 2006-11-16
US7094392B2 (en) 2006-08-22
US20040228807A1 (en) 2004-11-18
US7507397B2 (en) 2009-03-24
US7449172B2 (en) 2008-11-11
US6814954B2 (en) 2004-11-09
US20040126329A1 (en) 2004-07-01
US7601337B2 (en) 2009-10-13
US20040191181A1 (en) 2004-09-30
US20050089479A1 (en) 2005-04-28
US20060216243A1 (en) 2006-09-28
ES2324023T3 (en) 2009-07-29
US7491047B2 (en) 2009-02-17
US7070764B2 (en) 2006-07-04
EP1987823B1 (en) 2010-03-31
ES2341594T3 (en) 2010-06-22
DE60235852D1 (en) 2010-05-12
CA2447099A1 (en) 2002-11-28
US7005121B2 (en) 2006-02-28
US20040185008A1 (en) 2004-09-23
US20040186130A1 (en) 2004-09-23
US6884408B2 (en) 2005-04-26
US20030000518A1 (en) 2003-01-02
EP1990046B1 (en) 2010-03-31
EP1389099A1 (en) 2004-02-18
BE2013C054I2 (en) 2021-07-19
US20030007933A1 (en) 2003-01-09
FR13C0051I1 (en) 2013-09-27
US20040185002A1 (en) 2004-09-23
US7169378B2 (en) 2007-01-30
US20030021755A1 (en) 2003-01-30
US6780400B2 (en) 2004-08-24
US6737042B2 (en) 2004-05-18
EP1392262A1 (en) 2004-03-03
JP2004535403A (en) 2004-11-25
US6780399B2 (en) 2004-08-24
US7485285B2 (en) 2009-02-03
US20040126327A1 (en) 2004-07-01
US7070765B2 (en) 2006-07-04
US7045118B2 (en) 2006-05-16
US7078020B2 (en) 2006-07-18
US7087217B2 (en) 2006-08-08
US20040161385A1 (en) 2004-08-19
US20060216244A1 (en) 2006-09-28
US20040191185A1 (en) 2004-09-30
US7070761B2 (en) 2006-07-04
US20060257329A1 (en) 2006-11-16
ATE401063T1 (en) 2008-08-15
US20040126326A1 (en) 2004-07-01
US20060233719A1 (en) 2006-10-19
US7052680B2 (en) 2006-05-30
EP1389098A1 (en) 2004-02-18
US20030015190A1 (en) 2003-01-23
US20040202617A1 (en) 2004-10-14
US20030017117A1 (en) 2003-01-23
ATE462421T1 (en) 2010-04-15
US20030017119A1 (en) 2003-01-23
US7524484B2 (en) 2009-04-28
CA2446990A1 (en) 2002-11-28
US20040191180A1 (en) 2004-09-30
US20040170573A1 (en) 2004-09-02
EP1390021B1 (en) 2008-12-24
US20040185000A1 (en) 2004-09-23
DE60220909T2 (en) 2008-02-28
US6783753B2 (en) 2004-08-31
AU2002314784A1 (en) 2002-12-03
US6814955B2 (en) 2004-11-09
US6855310B2 (en) 2005-02-15
US20040191183A1 (en) 2004-09-30
US6805854B2 (en) 2004-10-19
US7014840B2 (en) 2006-03-21
PL364002A1 (en) 2004-11-29
US6803031B2 (en) 2004-10-12
CA2447521A1 (en) 2002-11-28
EP1987823A1 (en) 2008-11-05
US7078018B2 (en) 2006-07-18
US20060246011A1 (en) 2006-11-02
ATE425746T1 (en) 2009-04-15
JP5629151B2 (en) 2014-11-19
EP1392261B1 (en) 2008-12-31
US20040184999A1 (en) 2004-09-23
JP4578772B2 (en) 2010-11-10
CA2446990C (en) 2009-12-22
US7005122B2 (en) 2006-02-28
US20040156791A1 (en) 2004-08-12
NZ529416A (en) 2006-11-30
NZ529421A (en) 2006-11-30
NZ529420A (en) 2006-11-30
US20030206869A1 (en) 2003-11-06
US20070014737A1 (en) 2007-01-18
ATE365548T1 (en) 2007-07-15
JP2005503425A (en) 2005-02-03
US20070178052A1 (en) 2007-08-02
PT1389096E (en) 2009-06-12
US7018620B2 (en) 2006-03-28
ATE401064T1 (en) 2008-08-15
US20030017116A1 (en) 2003-01-23
US20060251587A1 (en) 2006-11-09
US7070766B2 (en) 2006-07-04
US7008615B2 (en) 2006-03-07
US6716415B2 (en) 2004-04-06
CA2446917A1 (en) 2002-11-28
EP1392259A2 (en) 2004-03-03
US20040185007A1 (en) 2004-09-23
US7048909B2 (en) 2006-05-23
AU2002310015B2 (en) 2008-09-04
US20060153779A1 (en) 2006-07-13
US20060251588A1 (en) 2006-11-09
US7063831B2 (en) 2006-06-20
US7063830B2 (en) 2006-06-20
EP1389095A1 (en) 2004-02-18
US7510702B2 (en) 2009-03-31
WO2002094236A1 (en) 2002-11-28
US7115250B2 (en) 2006-10-03
DK1389098T3 (en) 2008-11-10
US20040156788A1 (en) 2004-08-12
ATE406878T1 (en) 2008-09-15
US7449175B2 (en) 2008-11-11
US7011820B2 (en) 2006-03-14
JP2004531556A (en) 2004-10-14
US7465436B2 (en) 2008-12-16
EP1392264A1 (en) 2004-03-03
US20030021753A1 (en) 2003-01-30
NZ529418A (en) 2006-11-30
EP1389097B1 (en) 2008-08-13
US20060286042A1 (en) 2006-12-21
EP1990046A1 (en) 2008-11-12
JP4578773B2 (en) 2010-11-10
CA2447521C (en) 2009-12-29
EP1389094A1 (en) 2004-02-18
US7067114B2 (en) 2006-06-27
US20030017118A1 (en) 2003-01-23
DE60220909D1 (en) 2007-08-09
US20090246147A1 (en) 2009-10-01
US7022312B2 (en) 2006-04-04
US20030017115A1 (en) 2003-01-23
US20060177382A1 (en) 2006-08-10
CA2446917C (en) 2009-12-22
US8173107B2 (en) 2012-05-08
US7468179B2 (en) 2008-12-23
US7108847B2 (en) 2006-09-19
US20040170569A1 (en) 2004-09-02
US7033575B2 (en) 2006-04-25
US20040156790A1 (en) 2004-08-12
NZ529422A (en) 2006-11-30
US20040191182A1 (en) 2004-09-30
PL363997A1 (en) 2004-11-29
EP1392261A2 (en) 2004-03-03
US7063832B2 (en) 2006-06-20
US7070763B2 (en) 2006-07-04
CA2447099C (en) 2010-01-26
US7078017B2 (en) 2006-07-18
JP2010270138A (en) 2010-12-02
ATE418330T1 (en) 2009-01-15
PT1389098E (en) 2008-11-14
EP1392257A1 (en) 2004-03-03
US7060254B2 (en) 2006-06-13
ES2312571T3 (en) 2009-03-01
ATE418971T1 (en) 2009-01-15
EP1389094B1 (en) 2008-09-03
EP1392257B1 (en) 2008-07-16
EP1389096A1 (en) 2004-02-18
US7087216B2 (en) 2006-08-08
US20040185004A1 (en) 2004-09-23
EP1390021A1 (en) 2004-02-25
US20040126328A1 (en) 2004-07-01
US6716416B2 (en) 2004-04-06
DE60228232D1 (en) 2008-09-25
US6716417B2 (en) 2004-04-06
US7445768B2 (en) 2008-11-04
US20040156789A1 (en) 2004-08-12
US7449174B2 (en) 2008-11-11
US20040185001A1 (en) 2004-09-23
US20030015189A1 (en) 2003-01-23
US20040167228A1 (en) 2004-08-26
US20060269487A1 (en) 2006-11-30
US6797259B2 (en) 2004-09-28
US7507398B2 (en) 2009-03-24
US20050075273A1 (en) 2005-04-07
JP2004536805A (en) 2004-12-09
US20060239936A1 (en) 2006-10-26
EP1389098B1 (en) 2008-08-13
US7070762B2 (en) 2006-07-04
US20060286043A1 (en) 2006-12-21
US6776978B2 (en) 2004-08-17
US20040185005A1 (en) 2004-09-23
US7008616B2 (en) 2006-03-07
US20030012737A1 (en) 2003-01-16
US20040185006A1 (en) 2004-09-23
US6740307B2 (en) 2004-05-25
JP2004532859A (en) 2004-10-28
US20030017114A1 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
CA2446916A1 (en) Delivery of opioids through an inhalation route
WO2002094244A3 (en) Delivery of benzodiazepines through an inhalation route
WO2001097780A3 (en) Pharmaceutical compositions comprising an opioid analgesic
WO2004045551A3 (en) Pharmaceutical composition
JP2003528819A5 (en)
HUP0102658A2 (en) Pharmaceutical composition containing opioid agonist and antagonist combination
WO2009076236A3 (en) Micronized opioid compositions, formulations and dosage forms and methods of making same
AU5173701A (en) Method for improving lung delivery of pharmaceutical aerosols
CA2463938A1 (en) Polymer conjugates of opioid antagonists
JP2010511683A5 (en)
WO2002094218A3 (en) Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
CA2447210A1 (en) Delivery of aerosols containing small particles through an inhalation route
JP2008534564A5 (en)
CA2323805A1 (en) Analgesic combination comprising nmda receptor antagonists and narcotic analgesics
WO2004005294A3 (en) Morphinan derivatives the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof
HK1105174A1 (en) Aerosol delivery apparatus for pressure-assisted breathing systems
WO2005102431A3 (en) Aerosol delivery apparatus for pressure assisted breathing
NZ590952A (en) Use of opioid antagonists for treating urinary retention
AU2003217950A1 (en) Agglomerated particles for aerosol drug delivery
SG11201810557XA (en) Aerosol-generating article with an insulated heat source
NZ603170A (en) Combination of active loaded granules with additional actives
NZ619408A (en) Compositions and methods for prophylaxis and treatment of addictions
NZ631539A (en) Systems and methods for treating an opioid-induced adverse pharmacodynamic response
EP1083951A4 (en) Methods of delivering aerosolized polynucleotides to the respiratory tract
HUP0401022A3 (en) Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130521